- Home
- ANTX vs GDTC Comparison
ANTX vs GDTC Comparison
Compare ANTX & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANTX
- GDTC
- Stock Information
- Founded
- ANTX 2017
- GDTC 2018
- Country
- ANTX United States
- GDTC Singapore
- Employees
- ANTX N/A
- GDTC N/A
- Industry
- ANTX Biotechnology: Pharmaceutical Preparations
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- ANTX Health Care
- GDTC Health Care
- Exchange
- ANTX Nasdaq
- GDTC Nasdaq
- Market Cap
- ANTX 33.2M
- GDTC 28.0M
- IPO Year
- ANTX 2022
- GDTC 2023
- Fundamental
- Price
- ANTX $1.05
- GDTC $2.17
- Analyst Decision
- ANTX Buy
- GDTC Buy
- Analyst Count
- ANTX 2
- GDTC 1
- Target Price
- ANTX $2.00
- GDTC $5.00
- AVG Volume (30 Days)
- ANTX 286.6K
- GDTC 5.7K
- Earning Date
- ANTX 08-12-2025
- GDTC 01-01-0001
- Dividend Yield
- ANTX N/A
- GDTC N/A
- EPS Growth
- ANTX N/A
- GDTC N/A
- EPS
- ANTX N/A
- GDTC N/A
- Revenue
- ANTX N/A
- GDTC $368,838.00
- Revenue This Year
- ANTX N/A
- GDTC $5.37
- Revenue Next Year
- ANTX N/A
- GDTC N/A
- P/E Ratio
- ANTX N/A
- GDTC N/A
- Revenue Growth
- ANTX N/A
- GDTC N/A
- 52 Week Low
- ANTX $0.87
- GDTC $1.20
- 52 Week High
- ANTX $3.07
- GDTC $4.05
- Technical
- Relative Strength Index (RSI)
- ANTX 41.64
- GDTC 47.12
- Support Level
- ANTX $1.07
- GDTC $2.07
- Resistance Level
- ANTX $1.11
- GDTC $2.34
- Average True Range (ATR)
- ANTX 0.05
- GDTC 0.10
- MACD
- ANTX -0.00
- GDTC -0.00
- Stochastic Oscillator
- ANTX 0.00
- GDTC 41.00
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.